DE68923027D1 - Antigene. - Google Patents

Antigene.

Info

Publication number
DE68923027D1
DE68923027D1 DE68923027T DE68923027T DE68923027D1 DE 68923027 D1 DE68923027 D1 DE 68923027D1 DE 68923027 T DE68923027 T DE 68923027T DE 68923027 T DE68923027 T DE 68923027T DE 68923027 D1 DE68923027 D1 DE 68923027D1
Authority
DE
Germany
Prior art keywords
antigen
fragments
antigens
recognise
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68923027T
Other languages
English (en)
Inventor
Peter Stern
Nicholas Hole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888805240A external-priority patent/GB8805240D0/en
Priority claimed from GB888821078A external-priority patent/GB8821078D0/en
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Application granted granted Critical
Publication of DE68923027D1 publication Critical patent/DE68923027D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE68923027T 1988-03-04 1989-03-03 Antigene. Expired - Lifetime DE68923027D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888805240A GB8805240D0 (en) 1988-03-04 1988-03-04 Improvements relating to antigen
GB888821078A GB8821078D0 (en) 1988-09-08 1988-09-08 Improvements relating to antigens

Publications (1)

Publication Number Publication Date
DE68923027D1 true DE68923027D1 (de) 1995-07-20

Family

ID=26293590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68923027T Expired - Lifetime DE68923027D1 (de) 1988-03-04 1989-03-03 Antigene.

Country Status (6)

Country Link
EP (2) EP0403559A1 (de)
AT (1) ATE123652T1 (de)
AU (1) AU3353989A (de)
DE (1) DE68923027D1 (de)
IE (1) IE890720L (de)
WO (1) WO1989007947A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
AU715845B2 (en) * 1996-12-05 2000-02-10 Macquarie Research Limited Electrophoresis separation methods
AUPO403496A0 (en) * 1996-12-05 1997-01-02 Macquarie Research Limited Electrophoresis separation methods
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
JP2002507117A (ja) 1997-06-04 2002-03-05 オックスフォード・バイオメディカ・（ユーケイ）・リミテッド ベクター
US7767422B2 (en) 1998-09-22 2010-08-03 Oncomedx, Inc. Detection of 5T4 RNA in plasma and serum
GB2347932B (en) * 1998-11-18 2003-05-07 Oxford Biomedica Ltd Vectors for the delivery of 5T4 antigen
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
GB9825303D0 (en) * 1998-11-18 1999-01-13 Oxford Biomedica Ltd Vector
GB2370572B (en) * 1998-11-18 2003-05-07 Oxford Biomedica Ltd Use of a professional antigen presenting cell
GB2378704B (en) * 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
EP1354060B1 (de) * 2000-08-28 2011-02-09 Oncomedx, Inc. 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
EP1347994A2 (de) * 2000-11-13 2003-10-01 Oxford Biomedica (UK) Limited Tumorassoziiertes antigen 5t4 von hunden und katzen
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US7662625B2 (en) 2002-07-02 2010-02-16 Cancer Research Technology Limited Methods for detecting the differentiation status of cells using 5T4 antigen expression
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
EP2277918B1 (de) 2005-05-13 2012-11-14 Oxford BioMedica (UK) Limited Vom Tumorantigen 5t4 abgeleitete Mhc-Klasse-I- und II-Peptidantigene
CN101437850B (zh) 2006-03-10 2013-10-09 惠氏公司 抗5t4抗体及其用途
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP2411508B1 (de) 2009-03-27 2013-03-20 Wyeth LLC Tumorauslösende zellen und verfahren zur verwendung davon
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4015005A1 (de) 2011-10-03 2022-06-22 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US10254286B2 (en) 2012-01-24 2019-04-09 Pfizer Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
EP3380122B1 (de) 2015-11-24 2021-06-02 Byondis B.V. Antikörper gegen 5t4 und antikörper-wirkstoff-konjugate
JP7161938B2 (ja) 2016-01-10 2022-10-27 ネオティーエックス セラピューティクス リミテッド スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物
EP3595705A1 (de) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Verfahren
CN111227039A (zh) * 2018-11-29 2020-06-05 内蒙古伊利实业集团股份有限公司 脂肪球膜的提取方法、富含脂肪球膜的酸奶及制备方法
CA3139899A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2024077066A1 (en) * 2022-10-05 2024-04-11 Musc Foundation For Research Development Superantigen vaccine conjugate for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571146B1 (fr) * 1984-10-01 1988-02-26 Centre Nat Rech Scient Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant

Also Published As

Publication number Publication date
AU3353989A (en) 1989-09-22
EP0336562A1 (de) 1989-10-11
EP0403559A1 (de) 1990-12-27
ATE123652T1 (de) 1995-06-15
IE890720L (en) 1989-09-04
EP0336562B1 (de) 1995-06-14
WO1989007947A1 (en) 1989-09-08

Similar Documents

Publication Publication Date Title
DE68923027D1 (de) Antigene.
EP0823438A3 (de) Menschliches Mucin-Core-Protein: Peptid-Fragmente und Antikörper dagegen, sowohl deren Verwendung in Diagnoseverfahren und therapeutischen Methoden
DE69230545D1 (de) Antikörperderivate
NO942850D0 (de)
NO179615C (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
GR3029740T3 (en) Fragments of prion proteins.
EP1035132A4 (de) Monoklonale antikörper zur apoptosis-induzierung
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
EP0196319A4 (de) Retrovirale polypeptide in zusammenhang mit menschlicher transformation.
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
CA2185112A1 (en) Humanized monoclonal antibodies against human interleukin-4
EP0109434A4 (de) In vitro diagnoseverfahren unter verwendung von monoklonalen antikörpern gegen konnektive gewebeproteine.
DE3884646D1 (de) Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper.
AU616667B2 (en) Monoclonal antibodies against e7 protein of human type 16 papillomavirus, a process for their preparation, and their use
KR960009724B1 (en) Monoclonal antibodies against ifn-omega, process for preparing them and their use in purification
EP0307476A4 (en) Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
ES2059539T3 (es) Metodo para la prevencion de la enfermedad del injerto frente al huesped.
DE3855280D1 (de) Von mca 16-88 erkanntes antigen
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
NO872633L (no) Monoklonalt antistoff mot humant plasminogen, samt fremstilling derav.
NO895007D0 (no) Simultan enzym-immunoanalyse for deteksjon av antigen og/eller antistoff i mennesker.
NO914094D0 (no) Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer

Legal Events

Date Code Title Description
8332 No legal effect for de